Illumina, Inc. Stock 12‑Month Price Target Cut to $264.84, Implies 11% Upside
Analysts lowered Illumina's average price target from $267.47 to $264.84, with a range of $196 to $365. This implies an 11% upside from the Nov. 3 close. The consensus rating remains 'Buy' among 24 analysts, with 10 Buys, 10 Holds, and 4 Sells.
How this was made

The 30-second read
Why it matters
The slight downgrade may trigger short‑term selling pressure, though the consensus rating stays positive, limiting the move.
Market read
The price‑target cut is a modest, new piece of information that could influence short‑term trading decisions for Illumina.
What to watch
No new product or earnings data accompanies the target change, so the cut may reflect broader market risk aversion rather than company‑specific issues.
Background
Illumina is a leading provider of DNA sequencing and genomic analysis tools. Analyst consensus remains a Buy, but the average price target slipped slightly.
Ticker impact
Analysts lowered Illumina's average 12‑month price target to $264.84, down from $267.47.
downward pressure as the market prices in the lower target
A modest target reduction without new fundamental data typically leads to short‑term price weakness.
Market effects
Minor impact on the genomics/diagnostics sector as peers may be re‑rated similarly.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance; primarily affects Illumina shareholders.
Counterpoint
Some investors may view the modest cut as a buying opportunity given the still‑present 11% upside.
Key entities
- CompanyIllumina, Inc.
US‑listed genomics firm (ticker ILMN).


